How Glenmark knocked Merck flat in a 3-D world
This article was originally published in Scrip
Executive Summary
The recent dispute between Merck & Co and Glenmark over Glenmark’s sitagliptins (versions of Merck’s Januvia and Janument) shows that regulatory, administrative and legal variations around the globe can still befuddle multinational firms. Disentangling Merck’s learning journey through the controversial Section 3(d) of India's patent legislation illustrates how local factors make a difference.